Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

20201,452 citationsJournal Articlebronze Open Access

Authors

Christopher P. Cannon · Brigham and Women's Hospital

Richard E. Pratley · University of Tennessee Health Science Center

Samuel Dagogo‐Jack · University of Tennessee Health Science Center

James P. Mancuso · University of Tennessee Health Science Center

Susan Huyck · Merck & Co., Inc., Rahway, NJ, USA (United States)

Urszula Masiukiewicz · University of Tennessee Health Science Center

Abstract

Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).

Topics & Keywords

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Diabetes Management and Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 383, Issue 15, pp. 1425-1435

DOI: 10.1056/nejmoa2004967

Field-Weighted Citation Impact: 141.52